en
|
bg
News
Read Comac Medical’s news and connect with us at future events
Latest News
Coronavirus (COVID-19) Updates: FDA Authorizes Monoclonal Antibody for Treatment of COVID-19
November 9, 2020

On 09 November, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) for the investigational monoclonal antibody therapy bamlanivimab for the treatment of mild-to-moderate COVID-19 in adult and pediatric patients. The issuance of an EUA is different from FDA approval. In determining whether to issue an EUA, the FDA evaluates the available evidence and carefully balances any known or potential risks with any known or potential benefits of the product for use during an emergency. As part of the evaluation of the EUA, the agency imposed several quality measures to protect patients. The company owning the proprietary rights is required to implement these quality measures to manufacture this drug under the EUA.

Bamlanivimab is authorized for patients with positive results from direct SARS-CoV-2 viral testing who are 12 years of age and older weighing at least 40 kilograms (about 88 pounds), and who are at high risk for progressing to severe COVID-19 and/or hospitalization. This includes those who are 65 years of age or older, or who have certain chronic medical conditions.

While the safety and effectiveness of this investigational therapy continues to be evaluated, bamlanivimab was shown in clinical trials to reduce COVID-19-related hospitalization or emergency room visits in patients at high risk for disease progression within 28 days after treatment when compared to placebo.

Based on its review of the scientific evidence available, the FDA determined that it is reasonable to believe that bamlanivimab may be effective in treating non-hospitalized patients with mild or moderate COVID-19.

You can access the whole article here

Stay safe!

SUBMIT RFP